Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type (2 selected)

Type

Guidance programme

Showing 51 to 100 of 2046

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Neonatal infectionQS75
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancerTA946
Early and locally advanced breast cancer: diagnosis and managementNG101
Sebelipase alfa for treating Wolman diseaseHST30
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancerTA944
Intravascular lithotripsy for calcified arteries in peripheral arterial diseaseIPG780
Bipolar disorder: assessment and managementCG185
Epilepsies in children, young people and adultsQS211
Targeted-release budesonide for treating primary IgA nephropathyTA937
Ravulizumab for treating generalised myasthenia gravis (terminated appraisal)TA940
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal)TA941
Empagliflozin for treating chronic kidney diseaseTA942
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetesTA943
Risdiplam for treating spinal muscular atrophyTA755
Digitally enabled therapies for adults with anxiety disorders: early value assessmentHTE9
Middle meningeal artery embolisation for chronic subdural haematomasIPG779
Cardiovascular disease: risk assessment and reduction, including lipid modificationNG238
Transition from children's to adults' servicesQS140
Velmanase alfa for treating alpha-mannosidosisHST29
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancerTA939
Acne vulgaris: managementNG198
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal)TA938
Secukinumab for treating moderate to severe hidradenitis suppurativaTA935
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)TA936
Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolismIPG778
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)TA933
Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptomsTA934
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal)TA932
Percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosisIPG777
Zanubrutinib for treating chronic lymphocytic leukaemiaTA931
Transient loss of consciousness ('blackouts') in over 16sCG109
Hypertension in adults: diagnosis and managementNG136
Suspected acute respiratory infection in over 16s: assessment at first presentation and initial managementNG237
Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessmentHTE15
Biodegradable subacromial spacer insertion for rotator cuff tearsIPG775
Extracorporeal carbon dioxide removal for acute respiratory failureIPG776
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatmentsTA930
Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancerCG164
Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fractionTA929
Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodineTA928
Jaundice in newborn babies under 28 daysCG98
Pneumonia in adults: diagnosis and managementCG191
Acute respiratory infection in over 16s: initial assessment and management including virtual wards (hospital at home)QS210
Ranibizumab for treating diabetic macular oedemaTA274
Vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditionsIPG774
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitableTA917
Tirzepatide for treating type 2 diabetesTA924
Mirikizumab for treating moderately to severely active ulcerative colitisTA925
Baricitinib for treating severe alopecia areataTA926
Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal)TA923

Results per page

  1. 10
  2. 25
  3. 50
  4. All